CD11c.DTR mice develop a fatal fulminant myocarditis after local or systemic treatment with diphtheria toxin

Linda Männ1, Nora Kochupurakkal2, Christian Martin3

  • 1Institute for Experimental Immunology and Imaging, University Hospital, University Duisburg-Essen, Essen, Germany.

Insights

Diphtheria toxin (DTX) in CD11c.DTR mice causes fatal myocarditis, not lung issues, revealing a critical limitation for studying alveolar macrophages (AMs) and suggesting a new model for fulminant myocarditis.

Area of Science:

  • Immunology
  • Cardiology
  • Infectious Diseases

Background:

  • Alveolar macrophages (AMs) play a role in pulmonary Aspergillus fumigatus infections.
  • CD11c.DTR transgenic mice are used to deplete CD11c-expressing cells, including AMs.

Purpose of the Study:

  • To assess the role of AMs in A. fumigatus infection using CD11c.DTR mice.
  • To investigate unexpected adverse effects of diphtheria toxin (DTX) treatment in this model.

Main Methods:

  • Depletion of AMs via intratracheal DTX application in CD11c.DTR mice.
  • Infection with A. fumigatus (or sham treatment).
  • Assessment of lung function and cardiac pathology, including ECG.

Main Results:

  • DTX-treated CD11c.DTR mice exhibited high mortality (4-5 days), irrespective of fungal infection.
  • The cause of death was fulminant myocarditis (FM) with leukocyte infiltration and myocardial damage.
  • ECG revealed a Brugada-like pattern, indicating arrhythmia susceptibility.

Conclusions:

  • DTX treatment in CD11c.DTR mice causes severe myocarditis, limiting its use for studying lung immunity.
  • The CD11c.DTR mouse model shows potential for studying fulminant myocarditis.
  • Adverse effects of DTX in transgenic models require careful consideration.